Antiretroviral treatment of HIV-infected patients
| Treatment . | CX3CR1 function, no. of patients . | CX3CR1 expression, no. of patients . |
|---|---|---|
| — | 11 | 2 |
| 2 NRTI | 4 | 3 |
| 2 NRTI + 1 PI | 16 | 4 |
| 3 NRTI | 1 | — |
| 1 NRTI + 1 PI | 1 | 1 |
| 3 NRTI + 1 NNRTI + 1 PI | — | 1 |
| 2 NRTI + 1 NNRTI + 1 PI | 2 | 1 |
| 1 NRTI + 1 NNRTI + 1 PI | 2 | 1 |
| 1 NRTI + 1 NNRTI + 2 PI | — | 1 |
| 2 NRTI + 2 PI | 1 | — |
| Total | 38 | 14 |
| Treatment . | CX3CR1 function, no. of patients . | CX3CR1 expression, no. of patients . |
|---|---|---|
| — | 11 | 2 |
| 2 NRTI | 4 | 3 |
| 2 NRTI + 1 PI | 16 | 4 |
| 3 NRTI | 1 | — |
| 1 NRTI + 1 PI | 1 | 1 |
| 3 NRTI + 1 NNRTI + 1 PI | — | 1 |
| 2 NRTI + 1 NNRTI + 1 PI | 2 | 1 |
| 1 NRTI + 1 NNRTI + 1 PI | 2 | 1 |
| 1 NRTI + 1 NNRTI + 2 PI | — | 1 |
| 2 NRTI + 2 PI | 1 | — |
| Total | 38 | 14 |
The number of patients studied for CX3CR1 expression or function and treated with different regimens of ARV drugs is shown.
NRTI indicates nucleotide reverse transcriptase inhibitors; NNRTI, nonnucleotide reverse transcriptase inhibitors; PI, protease inhibitors.